VIVITROL is
one dose a month

Watch the Video to learn about
directions for use

Gluteal intramuscular injection of VIVITROL

Gluteal intramuscular injection of VIVITROL®

Vivitrol—a once-monthly
injectable

  • VIVITROL is only available in one dose, 380 mg, and must be administered by a healthcare professional
  • VIVITROL is given as a 4 mL gluteal intramuscular injection, delivering medication continuously over the approved dosing interval
  • VIVITROL must not be given intravenously, subcutaneously, or into adipose tissue
    • Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions

Injection site Reactions

  • VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe.
  • Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical intervention.
  • Select proper needle size for patient body habitus, and use only the needles provided in the carton.
  • Patients should be informed that any concerning injection site reactions should be brought to the attention of their healthcare provider.

VIVITROL IS ONE DOSE A MONTH

Continuous delivery of medication over the approved dosing interval

VIVITROL is an extended-release microsphere formulation of naltrexone that delivers medication continuously over a one-month period (or 4 weeks).1

MEAN NALTREXONE CONCENTRATION*2,3

Mean naltrexone concentration over 30 days

Continuous delivery of medication over the approved dosing interval

*Plasma concentrations do not necessarily correlate with clinical efficacy
Arrow Right

The recommended dose of VIVITROL is 380 mg, delivered intramuscularly once a month (every 4 weeks).

Arrow Right

Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.

Dosage and Administration:

Prior to initiating VIVITROL, an opioid-free duration of a minimum of 7–10 days is recommended for patients, to avoid precipitation of withdrawal that may be severe enough to require hospitalization.

VIVITROL is available in one dose, 380 mg, delivered intramuscularly every 4 weeks or once a month by a healthcare provider.

  • VIVITROL must not be administered intravenously or subcutaneously
  • Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions
  • Alternate buttocks for each subsequent injection
  • The needles provided in the carton are customized needles. VIVITROL must not be injected using any other needle. Proper needle from the carton should be selected based on body habitus
  • Administer with caution in patients with moderate to severe renal impairment, thrombocytopenia, or any other coagulation disorder
  • If a patient misses a dose, he/she should be instructed to receive the next dose as soon as possible

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, injection site reactions and sudden opioid withdrawal.
See Important Safety Information below. Discuss all benefits and risks with your patients. See Prescribing Information. Review Medication Guide with your patients.

Request a representative

REQUEST A REPRESENTATIVE

Request a visit from a VIVITROL representative to learn more about how VIVITROL may help your opioid- and alcohol-dependent patients.

REQUEST A REPRESENTATIVE

VIVITROL® Co-pay Savings Program

LEARN ABOUT THE VIVITROL® CO-PAY SAVINGS PROGRAM

Learn how the VIVITROL® Co-pay Savings Program may assist eligible* patients with out-of-pocket expenses for their VIVITROL prescriptions.

LEARN MORE

References:

  1. VIVITROL [prescribing information and medication guide]. Waltham, MA: Alkermes, Inc; rev December 2015.
  2. Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480-490.
  3. Dean RL. The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci. 2005 Jan;10:643-655.
*Eligibility for Alkermes-Sponsored Co-pay Assistance: Offer valid only for prescriptions for FDA-approved indications. You must be at least 18 years old. If you are purchasing your VIVITROL prescriptions with benefits from Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care or Alternative Benefit Plans (“ABPs”) under the Affordable Care Act; Medigap; Veterans Administration (“VA”); Department of Defense (“DoD”); TriCare®; or any similar state funded programs such as medical or pharmaceutical assistance programs, you are not eligible for this offer. Void where prohibited by law, taxed or restricted. Alkermes, Inc. reserves the right to rescind, revoke, or amend these offers without notice.